Samid Farooqui, MD
Internal Medicine · Oklahoma City, OKNPI 1740632181
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (51.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 62.9% of it on its own, with 32 other manufacturers making up the rest. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 366 payments — averaging $54.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$12K
- AstraZeneca$1K
- Sanofi$1K
- Boehringer Ingelheim$980
- GSK$876
- Regeneron Healthcare Solutions, Inc.$544
- plus $2K from 27 others
Across 3 payments — averaging $36,467 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$109K
What the payments were for
- Travel & lodging$2,12411%
- Food & beverage$7,46738%
- Education$10,19152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $12,443 |
| AstraZeneca(2 entities) | 37 | $1,354 |
| Sanofi | 42 | $1,146 |
| Boehringer Ingelheim | 48 | $980 |
| GSK | 85 | $876 |
| Regeneron Healthcare Solutions, Inc. | 27 | $544 |
| Actelion Pharmaceuticals US, Inc. | 13 | $424 |
| United Therapeutics Corporation | 9 | $218 |
| Amgen | 11 | $199 |
| Novartis | 11 | $187 |
| Sanofi-aventis U.S. LLC | 2 | $179 |
| Insmed, Inc. | 10 | $178 |
| Baxter Healthcare | 7 | $151 |
| Merck | 6 | $104 |
| AbbVie(2 entities) | 3 | $89 |
| La Jolla Pharmaceutical Company | 4 | $80 |
| Bayer | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Electromed, Inc. | 3 | $51 |
| Grifols USA, LLC | 2 | $46 |
| Olympus America Inc. | 1 | $45 |
| Johnson & Johnson | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Vifor Pharma, Inc. | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $33 |
| Gilead | 1 | $29 |
| Inogen, Inc. | 2 | $28 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| Fisher & Paykel Healthcare Inc | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,781 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 34 | $435,998 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 283 | $317,689 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 187 | $180,221 |
| XolairOmalizumab | 21 | $104,185 |
| Spiriva RespimatTiotropium Bromide | 132 | $101,602 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $96,995 |
| Fasenra PenBenralizumab | 14 | $89,036 |
| Dupixent PenDupilumab | 21 | $77,399 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 109 | $71,481 |
| SymbicortBudesonide/Formoterol Fumarate | 106 | $34,953 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $32,074 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $29,790 |
| Spiriva HandihalerTiotropium Bromide | 29 | $20,118 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 345 | $13,717 |
| DuleraMometasone/Formoterol | 26 | $11,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $980 | $609,081275 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $876 | $394,954403 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,354 | $215,174293 claims |
| Grifols USA, LLCProlastin C | $46 | $96,99511 claims |
| MerckDulera | $104 | $11,05726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
- Alisha SolomonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.